GEM-231

GEM231 is an 18mer antisense oligonucleotide targeting the mRNA of the PKA-I (RIα regulatory subunit of cAMP dependent protein kinase type I) . GEM231 induces cell growth arrest, apoptosis, and differentiation in a variety of cancer cell lines in vitro and in tumors in vivo.

Product Specifications

CAS Number

[255810-66-3]

Product Name Alternative

HYBO-165

UNSPSC

12352208

Target

PKA

Type

Reference compound

Related Pathways

Stem Cell/Wnt; TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/gem-231.html

Solubility

10 mM in DMSO

Smiles

[GEM-231]

References & Citations

[1]Agrawal S, Kandimalla ER, Yu D, et al. GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts. Int J Oncol. 2002;21 (1) :65-72.|[2]Mani S, Goel S, Nesterova M, et al. Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM 231) targeted against protein kinase A type I. Ann N Y Acad Sci. 2003;1002:252-262. |[3]Wang H, Hang J, Shi Z, et al. Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity. Int J Oncol. 2002;21 (1) :73-80.